B
Bull
Bull · 25%SCPH
$8.79
情境價格
$5.670
0.000 (0.00%)收盤時
Loading chart…
- High
- 5.705
- Open
- 5.680
- VWAP
- 5.67
- Vol
- 10.90M
- Mkt Cap
- 157.56M
- Low
- 5.650
- Amount
- 61.85M
- EV/EBITDA, TTM
- -2.59
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home.
Analyst Ratings (3)
+108.82% upside
Buy
3 Buy
0 Hold
0 Sell
Current: 5.67
最低
5.35
平均
11.84
最高
25.00
Maxim
Hold
—
2025-08-26
Maxim
2025-08-26
目標價
—
Hold
H.C. Wainwright
Buy
$9
2025-08-25
H.C. Wainwright
2025-08-25
目標價
$9
Buy
Craig-Hallum
Hold
$6
2025-08-25
Craig-Hallum
2025-08-25
目標價
$6
Hold
HC Wainwright & Co.
Strong Buy
$18
2025-03-20
HC Wainwright & Co.
2025-03-20
目標價
$18
Strong Buy
Maxim Group
Strong Buy
$12
2025-03-20
Maxim Group
2025-03-20
目標價
$12
Strong Buy
估值指標
The current forward P/E ratio for scPharmaceuticals Inc (SCPH) is -2.81, compared to its 5-year average forward P/E of -4.43.
Alphio AI Price Scenarios for SCPH
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Whales holding SCPH
事件時間軸
資訊
7.009-22PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BRY, SCPH, WKHS on Behalf of Shareholders
7.009-16PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SHCO, VRNT, SCPH on Behalf of Shareholders
7.009-16GlobenewswireSHAREHOLDER INQUIRY: Halper Sadeh LLC Probes ZIMV, ARIS, SCPH for Shareholder Interests
8.509-15GlobenewswireShareholder Notice: M&A Class Action Firm Probing the Merger Involving GTLS, SCPH, VTLE, and VRNT
7.008-28PRnewswireSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NWE, BKH, MURA, SCPH on Behalf of Shareholders
SCPH FAQ — answered by Alphio AI
scPharmaceuticals Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs. The Company’s strategy is to develop therapies for subcutaneous administration that have previously been limited to intravenous (IV) delivery. Its commercial product, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infuser. FUROSCIX is a formulation of furosemide contained in a pre-filled, Crystal Zenith cartridge and self- administered subcutaneously via a single-use, disposable and wearable on-body delivery system. The Company’s pipeline programs include SCP-111 (furosemide injection) 80mg/mL is an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
3 analysts cover SCPH: 3 rate it Buy, 0 Hold and 0 Sell. The average price target is 11.84.
本頁僅供研究參考，不構成投資建議。模型可能出錯。過往表現不代表未來結果。